Identification of a thermogenic target in the dorsal raphe nucleus for weight management in mice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moura-Assis Alexandre, Plucińska Kaja, Meseguer David, Baleisyte Aiste, Chen Bandy, Pellegrino Kyle, Parolari Luca, Shaked Jordan T, Page Keith J, Barrows Douglas W, Carroll Thomas S, Grajales-Reyes Jose G, Na Daxiang, Rodriguez-Diaz Amanda, Furtado Jessica, Isaza Juan Uribe, Schiffer Hans H, Chen Yun, Sun Huikai, Kaushal Nidhi, Monenschein Holger, Barker Daniel F, Ortuño María José, Renier Nicolas, Cohen Paul, Carlton Mark, Heintz Nathaniel, Brice Nicola L, Friedman Jeffrey M, Schneeberger Marc
Аннотация
Obesity emerges from a complex interplay of factors, including imbalanced interoception, genetic predisposition, and environmental cues, which ultimately disrupt body weight homeostasis1. While much research has concentrated on strategies to suppress appetite for sustained weight loss, insufficient attention has been given to counterregulatory mechanisms that promote energy expenditure. Here, we show that chronic inhibition of GABAergic neurons in the dorsal raphe nucleus and ventrolateral periaqueductal gray (DRN/vlPAGVGAT) reduces body weight in diet-induced obese (DIO) male mice. In this study, molecular profiling and in-situ hybridization in rodent and human brains revealed that the constitutively activated orphan receptor GPR6 is selectively enriched in DRN/vlPAGVGAT neurons. We next developed and administered a potent and highly selective GPR6 inverse agonist, which significantly prevented weight gain in male mice exposed to a high-fat diet by stimulating brown adipose tissue thermogenesis without affecting appetite. Altogether, this study integrates transcriptomic profiling, high-throughput drug screening and metabolic phenotyping to successfully identify a candidate to treat obesity.